Rucaparib in refractory pleural mesothelioma harboring somatic pathogenic BRCA1 and BRCA2 mutation. A report of two cases
Year: 2024
Type: article
Study design: Case Report
Abstract: Pleural mesothelioma is a rare disease with few therapeutic options, especially in the first line refractory setting. Targeted agents did not demonstrate a significant clinical benefit in mesothelioma treatment, nevertheless a small group of patients might harbor potentially actionable somatic mutations, as in homologous repair recombination genes. In this paper we report two cases of patients with heavily pretreated pleural mesothelioma that had a relevant clinical benefit with rucaparib treatment based on somatic BRCA 1 and BRCA 2 mutations detected through next generation sequencing.
Source: Lung Cancer Management
Authors: Luigi Cerbone, Benedetta del Rio, Sara Delfanti, Francesco Boccuzzi, Paola Barbieri, Antonina Maria De Angelis, Stefano Meda, Laura Savi, Luisella Righi, Marika Sculco, Irma Dianzani, Paolo Bironzo, Federica Grosso
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W4405010299